ExodusPoint Capital Management LP Makes New Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

ExodusPoint Capital Management LP acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,761 shares of the company’s stock, valued at approximately $1,529,000.

Other hedge funds have also added to or reduced their stakes in the company. Entropy Technologies LP purchased a new position in shares of Krystal Biotech in the fourth quarter worth about $548,000. Janney Montgomery Scott LLC grew its stake in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after acquiring an additional 15,545 shares in the last quarter. Principal Financial Group Inc. grew its stake in Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock valued at $19,340,000 after acquiring an additional 3,727 shares in the last quarter. abrdn plc grew its stake in Krystal Biotech by 32.5% during the fourth quarter. abrdn plc now owns 57,033 shares of the company’s stock valued at $8,935,000 after acquiring an additional 13,979 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after acquiring an additional 433 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $168.16 on Thursday. The company has a market capitalization of $4.84 billion, a price-to-earnings ratio of 56.24 and a beta of 0.75. The company’s 50-day moving average is $173.85 and its 200 day moving average is $172.48. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the business earned $0.30 EPS. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on KRYS shares. Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).